GlassScriptPhysician profile
Jeffrey David Caughran
NPI 1700177482
$1,026.45
in general payments reported to CMS, 2019-2025
26 companies · $929 in 2025
The $929 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.87 · 2021: $34.03 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $108.77 | 2025 | Imfinzi, Calquence, Lynparza |
| Beone Medicines USA, INC. | $80.68 | 2025 | Brukinsa, Tevimbra |
| Genentech USA, INC. | $75.15 | 2021-2025 | Polivy, Tecentriq |
| Novartis Pharmaceuticals Corporation | $66.60 | 2025 | |
| Janssen Biotech, INC. | $53.90 | 2025 | Rybrevant, Carvykti, Erleada |
| Daiichi Sankyo INC. | $52.56 | 2025 | Datroway, Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.41 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $45.20 | 2025 | Lynozyfic, Libtayo |
| Incyte Corporation | $41.66 | 2025 | Zynyz, Monjuvi, Jakafi |
| Immunocore Limited | $41.46 | 2025 | Kimmtrak |
| E.R. Squibb & Sons, L.L.C. | $40.37 | 2025 | Opdivo |
| Pfizer INC. | $39.23 | 2019-2025 | |
| Tersera Therapeutics LLC | $33.96 | 2025 | Zoladex |
| Alexion Pharmaceuticals, INC. | $31.15 | 2019 | |
| Glaxosmithkline, LLC. | $30.78 | 2025 | Jemperli, Ojjaara |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $25.63 | 2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $23.73 | 2025 | Keytruda Qlex, Keytruda, Lynparza |
| Spectrum Pharmaceuticals INC. | $22.81 | 2025 | Rolvedon |
| Celgene Corporation | $21.83 | 2025 | Reblozyl |
| Genmab U.S., INC. | $21.72 | 2025 | Epkinly |
| Array Biopharma INC | $19.95 | 2025 | Braftovi, Lorbrena, Mektovi |
| Emd Serono, INC. | $19.64 | 2025 | |
| Lilly USA, LLC | $19.64 | 2025 | Jaypirca, Verzenio |
| Rigel Pharmaceuticals, INC. | $16.25 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Servier Pharmaceuticals LLC | $15.82 | 2025 | |
| Eisai INC. | $14.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Caughran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.